ES2174757B1 - Empleo de derivados de firazolinas en la elaboracion de un medicamentopara la prevencion y/o el tratamiento de enfermedades proliferativas celulares. - Google Patents

Empleo de derivados de firazolinas en la elaboracion de un medicamentopara la prevencion y/o el tratamiento de enfermedades proliferativas celulares.

Info

Publication number
ES2174757B1
ES2174757B1 ES200100818A ES200100818A ES2174757B1 ES 2174757 B1 ES2174757 B1 ES 2174757B1 ES 200100818 A ES200100818 A ES 200100818A ES 200100818 A ES200100818 A ES 200100818A ES 2174757 B1 ES2174757 B1 ES 2174757B1
Authority
ES
Spain
Prior art keywords
methyl
hydrogen
trifluoromethyl
fluorine
prevention
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
ES200100818A
Other languages
English (en)
Other versions
ES2174757A1 (es
Inventor
Maria Rosa Cuberes-Altisent
Juana Maria Berrocal-Romero
M Montserrat Contijoch-Llobet
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Esteve Pharmaceuticals SA
Original Assignee
Laboratorios del Dr Esteve SA
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority to ES200100818A priority Critical patent/ES2174757B1/es
Application filed by Laboratorios del Dr Esteve SA filed Critical Laboratorios del Dr Esteve SA
Priority to DE60211681T priority patent/DE60211681T2/de
Priority to NZ529304A priority patent/NZ529304A/en
Priority to AT02714233T priority patent/ATE326966T1/de
Priority to HU0400918A priority patent/HUP0400918A3/hu
Priority to US10/312,193 priority patent/US20040034082A1/en
Priority to EP04030751A priority patent/EP1516621A3/en
Priority to IL15826902A priority patent/IL158269A0/xx
Priority to CNA2005100713090A priority patent/CN1698602A/zh
Priority to DK02714233T priority patent/DK1384477T3/da
Priority to ES02714233T priority patent/ES2264723T3/es
Priority to SI200230345T priority patent/SI1384477T1/sl
Priority to ZA200308626A priority patent/ZA200308626B/en
Priority to BR0208805-3A priority patent/BR0208805A/pt
Priority to AU2002246152A priority patent/AU2002246152B2/en
Priority to PL02365220A priority patent/PL365220A1/xx
Priority to CNB028098935A priority patent/CN1299682C/zh
Priority to JP2002578948A priority patent/JP4451599B2/ja
Priority to PCT/ES2002/000137 priority patent/WO2002080909A1/es
Priority to PT02714233T priority patent/PT1384477E/pt
Priority to MXPA03009124A priority patent/MXPA03009124A/es
Priority to KR10-2003-7013062A priority patent/KR20040025912A/ko
Priority to UA2003119998A priority patent/UA75402C2/uk
Priority to CA2442974A priority patent/CA2442974C/en
Priority to RU2003132457/15A priority patent/RU2305545C2/ru
Priority to EP02714233A priority patent/EP1384477B1/en
Publication of ES2174757A1 publication Critical patent/ES2174757A1/es
Priority to IS6973A priority patent/IS6973A/is
Priority to NO20034470A priority patent/NO20034470L/no
Publication of ES2174757B1 publication Critical patent/ES2174757B1/es
Application granted granted Critical
Priority to MA27382A priority patent/MA27019A1/fr
Priority to HK04110341A priority patent/HK1067311A1/xx
Priority to CY20061101088T priority patent/CY1105523T1/el
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
    • C07D231/02—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
    • C07D231/06—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/415—1,2-Diazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Vascular Medicine (AREA)
  • Oncology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Urology & Nephrology (AREA)
  • Endocrinology (AREA)
  • Reproductive Health (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

Empleo de derivados de pirazolinas en la elaboración de un medicamento para la prevención y/o el tratamiento de enfermedades proliferativas celulares. Los derivados de pirazolina (I), donde R1 es hidrógeno, metilo, fluorometilo, difluorometilo, trifluorometilo, ácido carboxílico, carboxilato de alquilo inferior de 1 a 4 átomos de carbono, carboxamida o ciano, R2 es hidrógeno o metilo, R3, R4, R7 y R8, independientemente son hidrógeno, cloro, flúor, metilo, trifluorometilo o metoxi, R5 y R6, independientemente entre sí, son hidrógeno, cloro, flúor, metilo, trifluorometilo, metoxi, trifluorometoxi, metilsulfonilo, aminosulfonilo o acetilaminosulfonilo, con la condición de que uno de los sustituyentes R5 o R6 es un grupo metilsulfonilo, aminosulfonilo o acetilaminosulfonilo, y con la condición de que cuando R1 es metilo, entonces R2 es hidrógeno o metilo, R3 y R8, independientemente, son hidrógeno, cloro, flúor, metilo, o trifluorometilo, R4 es hidrógeno, flúor, metilo, trifluorometilo o metoxi, R5 es flúor, trifluorometilo, trifluorometoxi, metilsulfonilo, aminosulfonilo o acetilaminosulfonilo, R6 es hidrógeno, cloro, flúor, metilo, trifluorometilo, metoxi, trifluorometoxi, metilsulfonilo, aminosulfonilo o acetilaminosulfonilo, con la condición de que uno de los sustituyentes R5 o R6 es un grupo metilsulfonilo, aminosulfonilo o acetilaminosulfonilo, y R7 representa un átomo de hidrógeno, cloro, flúor, un grupo metilo, trifluorometilo o metoxi; son útiles para la prevención o el tratamiento de enfermedades proliferativas celulares.
ES200100818A 2001-04-06 2001-04-06 Empleo de derivados de firazolinas en la elaboracion de un medicamentopara la prevencion y/o el tratamiento de enfermedades proliferativas celulares. Expired - Fee Related ES2174757B1 (es)

Priority Applications (31)

Application Number Priority Date Filing Date Title
ES200100818A ES2174757B1 (es) 2001-04-06 2001-04-06 Empleo de derivados de firazolinas en la elaboracion de un medicamentopara la prevencion y/o el tratamiento de enfermedades proliferativas celulares.
PCT/ES2002/000137 WO2002080909A1 (es) 2001-04-06 2002-03-21 Empleo de derivados de pirazolinas en la elaboración de un medicamento para la prevención y/o el tratamiento de enfermedades proliferativas celulares
AT02714233T ATE326966T1 (de) 2001-04-06 2002-03-21 Verwendung von pyrazolinderivativen bei der herstellung eines medikaments zur prävention und/oder behandlung von proliferativen zellerkrankungen
NZ529304A NZ529304A (en) 2001-04-06 2002-03-21 Utilization of pyrazoline derivatives in the preparation of a medicament for the prevention and/or treatment of proliferative cell diseases
US10/312,193 US20040034082A1 (en) 2001-04-06 2002-03-21 Utilization of pyrazoline derivatives in the preparation of a medicament for the prevention and/or treatment of proliferative cell diseases
PT02714233T PT1384477E (pt) 2001-04-06 2002-03-21 Utilizacao de derivados de pirazolina na preparacao de um medicamento para a prevencao e/ou tratamento de doencas proliferativas celulares
IL15826902A IL158269A0 (en) 2001-04-06 2002-03-21 Utilization of pyrazoline derivatives in the preparation of a medicament for the prevention and/or treatment of proliferative cell diseases
CNA2005100713090A CN1698602A (zh) 2001-04-06 2002-03-21 吡唑啉衍生物在用于预防和/或治疗细胞增殖疾病的药物制备中的用途
DK02714233T DK1384477T3 (da) 2001-04-06 2002-03-21 Anvendelse af pyrazolinderivater ved fremstilling af et medikament til forebyggelse og/eller behandling af proliferative cellesygdomme
ES02714233T ES2264723T3 (es) 2001-04-06 2002-03-21 Uso de derivados de pirazolina en la preparacion de un medicamento para la prevencion y/o el tratamiento de enfermedades proliferativas celulares.
SI200230345T SI1384477T1 (sl) 2001-04-06 2002-03-21 Uporaba derivatov pirazolina pri pripravi zdravila za preprecevanje in/ali zdravljenje proliferatnih celicnih bolezni
ZA200308626A ZA200308626B (en) 2001-04-06 2002-03-21 Utilization of pyrazoline derivatives in the preparation of a medicament for the prevention and/or treatment of poroliferative cell diseases.
BR0208805-3A BR0208805A (pt) 2001-04-06 2002-03-21 Uso de um derivado de pirazolina
AU2002246152A AU2002246152B2 (en) 2001-04-06 2002-03-21 Utilization of pyrazoline derivatives in the preparation of a medicament for the prevention and/or treatment of proliferative cell diseases
PL02365220A PL365220A1 (en) 2001-04-06 2002-03-21 Utilization of pyrazoline derivatives in the preparation of a medicament for the prevention and/or treatment of proliferative cell diseases
CNB028098935A CN1299682C (zh) 2001-04-06 2002-03-21 吡唑啉衍生物在用于预防和/或治疗细胞增殖疾病的药物制备中的用途
DE60211681T DE60211681T2 (de) 2001-04-06 2002-03-21 Verwendung von pyrazolinderivativen bei der herstellung eines medikaments zur prävention und/oder behandlung von proliferativen zellerkrankungen
HU0400918A HUP0400918A3 (en) 2001-04-06 2002-03-21 Utilization of pyrazoline derivatives in the preparation of pharmaceutical compositions for the prevention and/or treatment of proliferative cell diseases
EP04030751A EP1516621A3 (en) 2001-04-06 2002-03-21 Use of pyrazoline derivatives in the preparation of a medicament for the prevention and/or treatment of cell proliferation diseases
MXPA03009124A MXPA03009124A (es) 2001-04-06 2002-03-21 Empleo de derivados de pirazolinas en la elaboracion de un medicamento para la prevencion y/o el tratamiento de enfermedades proliferativas celulares.
KR10-2003-7013062A KR20040025912A (ko) 2001-04-06 2002-03-21 세포 증식 질환의 예방 및/또는 치료를 위한 약물의제조에서 피라졸린 유도체의 용도
UA2003119998A UA75402C2 (en) 2001-04-06 2002-03-21 Use of pyrazoline derivative for the preparation of medicament for prevention or treatment of proliferative cellular diseases
CA2442974A CA2442974C (en) 2001-04-06 2002-03-21 Use of pyrazoline derivatives in the preparation of a medicament for the prevention and/or treatment of cell proliferation diseases
RU2003132457/15A RU2305545C2 (ru) 2001-04-06 2002-03-21 Применение производных пиразолина при получении лечебного средства для предупреждения и/или лечения болезней, связанных с пролиферацией клеток
EP02714233A EP1384477B1 (en) 2001-04-06 2002-03-21 Utilization of pyrazoline derivatives in the preparation of a medicament for the prevention and/or treatment of proliferative cell diseases
JP2002578948A JP4451599B2 (ja) 2001-04-06 2002-03-21 細胞増殖疾患の予防及び／又は治療薬の調製におけるピラゾリン誘導体の使用
IS6973A IS6973A (is) 2001-04-06 2003-10-03 Notkun pýrasólínafleiða í framleiðslu á lyfi til að fyrirbyggja og/eða meðhöndla frumufjölgunarsjúkdóma
NO20034470A NO20034470L (no) 2001-04-06 2003-10-06 Anvendelse av pyrazolin-derivater ved fremstilling av et medikament for forebygging og/eller behandling av proliferasjonssykdommer
MA27382A MA27019A1 (fr) 2001-04-06 2003-11-05 Utilisation des derives de la pyrazoline dans la preparation d'un medicament pour la prevention et/ou le traitement des maladies de la proliferation des cellules.
HK04110341A HK1067311A1 (en) 2001-04-06 2004-12-30 Utilization of pyrazoline derivatives in the preparation of a medicament for the prevention and/or treatment of proliferative cell diseases
CY20061101088T CY1105523T1 (el) 2001-04-06 2006-08-03 Χρηση παραγωγων της πυραζολινης κατα την παρασκευη ενος φαρμακου για την προληψη και/ή την υποβολη σε θεραπευτικη αγωγη ασθενειων πολλαπλασιασμου των κυτταρων

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
ES200100818A ES2174757B1 (es) 2001-04-06 2001-04-06 Empleo de derivados de firazolinas en la elaboracion de un medicamentopara la prevencion y/o el tratamiento de enfermedades proliferativas celulares.

Publications (2)

Publication Number Publication Date
ES2174757A1 ES2174757A1 (es) 2002-11-01
ES2174757B1 true ES2174757B1 (es) 2003-11-01

Family

ID=8497370

Family Applications (2)

Application Number Title Priority Date Filing Date
ES200100818A Expired - Fee Related ES2174757B1 (es) 2001-04-06 2001-04-06 Empleo de derivados de firazolinas en la elaboracion de un medicamentopara la prevencion y/o el tratamiento de enfermedades proliferativas celulares.
ES02714233T Expired - Lifetime ES2264723T3 (es) 2001-04-06 2002-03-21 Uso de derivados de pirazolina en la preparacion de un medicamento para la prevencion y/o el tratamiento de enfermedades proliferativas celulares.

Family Applications After (1)

Application Number Title Priority Date Filing Date
ES02714233T Expired - Lifetime ES2264723T3 (es) 2001-04-06 2002-03-21 Uso de derivados de pirazolina en la preparacion de un medicamento para la prevencion y/o el tratamiento de enfermedades proliferativas celulares.

Country Status (27)

Country Link
US (1) US20040034082A1 (es)
EP (2) EP1384477B1 (es)
JP (1) JP4451599B2 (es)
KR (1) KR20040025912A (es)
CN (2) CN1299682C (es)
AT (1) ATE326966T1 (es)
AU (1) AU2002246152B2 (es)
BR (1) BR0208805A (es)
CA (1) CA2442974C (es)
CY (1) CY1105523T1 (es)
DE (1) DE60211681T2 (es)
DK (1) DK1384477T3 (es)
ES (2) ES2174757B1 (es)
HK (1) HK1067311A1 (es)
HU (1) HUP0400918A3 (es)
IL (1) IL158269A0 (es)
IS (1) IS6973A (es)
MA (1) MA27019A1 (es)
MX (1) MXPA03009124A (es)
NO (1) NO20034470L (es)
NZ (1) NZ529304A (es)
PL (1) PL365220A1 (es)
PT (1) PT1384477E (es)
RU (1) RU2305545C2 (es)
UA (1) UA75402C2 (es)
WO (1) WO2002080909A1 (es)
ZA (1) ZA200308626B (es)

Families Citing this family (35)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2005212833A1 (en) * 2004-02-16 2005-08-25 Laboratorios Del Dr. Esteve S.A. Pyrazoline derivatives useful for the treatment of cancer
ES2238923B1 (es) * 2004-02-16 2006-11-01 Laboratorios Del Dr. Esteve, S.A. Nuevos derivados pirazolinicos sustituidos.
EP1637522A1 (en) * 2004-09-16 2006-03-22 Laboratorios Del Dr. Esteve, S.A. Substituted pyrazoline compounds for reducing triglycerides in blood
EP1718619A1 (en) * 2004-02-17 2006-11-08 Laboratorios del Dr. Esteve S.A. Substituted pyrazoline compounds for reducing triglycerides in blood
US7998996B2 (en) 2004-02-17 2011-08-16 Laboratorios Del Dr. Esteve S.A. Substituted pyrazoline compounds for reducing triglycerides in blood
TW200533657A (en) 2004-02-17 2005-10-16 Esteve Labor Dr Substituted pyrazoline compounds, their preparation and use as medicaments
EP1746090A1 (en) * 2005-07-15 2007-01-24 Laboratorios del Dr. Esteve S.A. Sustituted pyrazoline compounds, having predetermined stereochemistry, for reducing triglycerides in blood
EP1743892A1 (en) * 2005-07-15 2007-01-17 Laboratorios del Dr. Esteve S.A. Substituted pyrazoline compounds, their preparation and use as medicaments
WO2007009706A2 (en) * 2005-07-15 2007-01-25 Laboratorios Del Dr. Esteve, S.A. Substituted pyrazoline compounds, having predetermined stereochemistry, for reducing triglycerides in blood
EP1743889A1 (en) * 2005-07-15 2007-01-17 Laboratorios del Dr. Esteve S.A. Sustituted pyrazoline compounds, having predetermined stereochemistry, for reducing triglycerides in blood
EP1749527A1 (en) * 2005-07-15 2007-02-07 Laboratorios Del Dr. Esteve, S.A. Use of substituted pyrazoline compounds for the treatment of the lipid parameters of the metabolic syndrome
EP1743637A1 (en) * 2005-07-15 2007-01-17 Laboratorios Del Dr. Esteve, S.A. Use of substituted pyrazole compounds and combinations thereof for the treatment of the metabolic syndrome
WO2007009700A2 (en) * 2005-07-15 2007-01-25 Laboratorios Del Dr. Esteve, S.A. Use of substituted pyrazoline compounds for the treatment of the lipid parameters of the metabolic syndrome
ES2336883B1 (es) * 2005-07-15 2011-03-22 Laboratorios Del Dr. Esteve, S.A. Compuestos de pirazolina sustituidos, con una estereoquimica predeterminada, para la reduccion de trigliceridos en sangre.
EP1749526A1 (en) * 2005-07-15 2007-02-07 Laboratorios Del Dr. Esteve, S.A. Use of substituted pyrazoline compounds for the treatment of food disorders, including obesity or metabolic syndrome in patients with developed diabetes
ES2327379B1 (es) * 2005-07-15 2010-05-28 Laboratorios Del Dr. Esteve, S.A. Compuestos de pirazolina indolinsustituidos, su preparacion y su uso como medicamentos.
EP1749525A1 (en) * 2005-07-15 2007-02-07 Laboratorios Del Dr. Esteve, S.A. Combination of substituted pyrazolines and anti-addictive agent
EP1743636A1 (en) * 2005-07-15 2007-01-17 Laboratorios Del Dr. Esteve, S.A. Combination of a substituted pyrazoline compound and a drug used in food-related disorders
EP1743639A1 (en) * 2005-07-15 2007-01-17 Laboratorios Del Dr. Esteve, S.A. Use of substituted pyrazoline compounds for the treatment of coagulation related diseases
WO2007009701A2 (en) * 2005-07-15 2007-01-25 Laboratorios Del Dr. Esteve, S.A. Use of substituted pyrazole compounds and combinations thereof for the treatment of the metabolic syndrome
WO2007009707A2 (en) * 2005-07-15 2007-01-25 Laboratorios Del Dr. Esteve, S.A. Use of substituted pyrazoline compounds for the treatment of coagulation related diseases
WO2007009703A2 (en) * 2005-07-15 2007-01-25 Laboratorios Del Dr. Esteve, S.A. New formulations of substituted pyrazoline compounds
EP1743643A1 (en) * 2005-07-15 2007-01-17 Laboratorios Del Dr. Esteve, S.A. New formulations of substituted pyrazoline compounds
US7897589B2 (en) 2005-07-15 2011-03-01 Laboratorios Del Dr. Esteve, S.A. Substituted pyrazoline compounds, their preparation and use as medicaments
WO2007009704A2 (en) * 2005-07-15 2007-01-25 Laboratorios Del Dr. Esteve, S.A. Use of substituted pyrazoline compounds for the treatment of food disorders, including obesity or metabolic syndrome in patients with developed diabetes
WO2007009699A2 (en) * 2005-07-15 2007-01-25 Laboratorios Del Dr. Esteve, S.A Use of substituted pyrazoline compounds and their derivatives for the treatment of cannabinoid system-associated diseases
WO2007009693A1 (en) * 2005-07-15 2007-01-25 Laboratorios Del Dr.Esteve, S.A Combination of a substituted pyrazoline compound and a drug used in food-related disorders
EP1743890A1 (en) 2005-07-15 2007-01-17 Laboratorios Del Dr. Esteve, S.A. 4,5-Dihydro-1H-pyrazole derivatives, their preparation and use as medicaments
EP1849776A1 (en) * 2006-04-26 2007-10-31 Laboratorios Del Dr. Esteve, S.A. Azepane- or Azocane-substituted pyrazoline compounds, their preparation and use as medicaments
WO2007009691A2 (en) * 2005-07-15 2007-01-25 Laboratorios Del Dr. Esteve, S.A. Combination of substituted pyrazolines and anti -addictive agent
EP1849784A1 (en) * 2006-04-26 2007-10-31 Laboratorios Del Dr. Esteve, S.A. Indoline-substituted pyrazoline compounds, their preparation and use as medicaments
EP1743642A1 (en) * 2005-07-15 2007-01-17 Laboratorios Del Dr. Esteve, S.A. Use of substituted pyrazoline compounds and their derivatives for the treatment of cannabinoid system-associated diseases
KR101457637B1 (ko) * 2012-10-24 2014-11-20 건국대학교 산학협력단 디히드로피라졸카르보티오아미드 유도체 및 그 제법 및 그 유도체를 포함하는 항암제 조성물
CN103664785A (zh) * 2013-11-04 2014-03-26 南京大学 一类新颖的二氢吡唑磺胺衍生物的合成及在抗癌药物中的应用
WO2023043778A1 (en) * 2021-09-14 2023-03-23 Maverick Gold (Nv), Llc Methods and systems for titling and trading alternative reserves

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5604253A (en) * 1995-05-22 1997-02-18 Merck Frosst Canada, Inc. N-benzylindol-3-yl propanoic acid derivatives as cyclooxygenase inhibitors
US5972986A (en) * 1997-10-14 1999-10-26 G.D. Searle & Co. Method of using cyclooxygenase-2 inhibitors in the treatment and prevention of neoplasia
ES2137138B1 (es) * 1998-05-29 2000-09-16 Esteve Labor Dr Derivados de pirazolinas, su preparacion y su aplicacion como medicamentos.
JP2003501464A (ja) * 1999-06-16 2003-01-14 テンプル・ユニバーシティ−オブ・ザ・コモンウェルス・システム・オブ・ハイアー・エデュケイション シクロオキシゲナーゼ−２の阻害剤としての１−（４−スルファミルアリール）−３−置換−５−アリール−２−ピラゾリン

Also Published As

Publication number Publication date
ES2264723T3 (es) 2007-01-16
US20040034082A1 (en) 2004-02-19
ZA200308626B (en) 2004-11-05
NZ529304A (en) 2006-02-24
HK1067311A1 (en) 2005-04-08
MXPA03009124A (es) 2005-04-11
RU2305545C2 (ru) 2007-09-10
CA2442974C (en) 2010-02-23
EP1384477B1 (en) 2006-05-24
NO20034470D0 (no) 2003-10-06
PT1384477E (pt) 2006-09-29
NO20034470L (no) 2003-12-05
EP1384477A1 (en) 2004-01-28
EP1516621A2 (en) 2005-03-23
MA27019A1 (fr) 2004-12-20
JP2004525166A (ja) 2004-08-19
WO2002080909A1 (es) 2002-10-17
ATE326966T1 (de) 2006-06-15
HUP0400918A3 (en) 2004-10-28
HUP0400918A2 (hu) 2004-07-28
CN1698602A (zh) 2005-11-23
DK1384477T3 (da) 2006-08-21
CN1299682C (zh) 2007-02-14
AU2002246152B2 (en) 2007-05-31
IL158269A0 (en) 2004-05-12
CN1509171A (zh) 2004-06-30
UA75402C2 (en) 2006-04-17
KR20040025912A (ko) 2004-03-26
ES2174757A1 (es) 2002-11-01
EP1516621A3 (en) 2005-05-04
DE60211681T2 (de) 2007-05-16
RU2003132457A (ru) 2005-04-10
JP4451599B2 (ja) 2010-04-14
IS6973A (is) 2003-10-03
BR0208805A (pt) 2004-07-13
PL365220A1 (en) 2004-12-27
DE60211681D1 (de) 2006-06-29
CA2442974A1 (en) 2002-10-17
CY1105523T1 (el) 2010-07-28

Similar Documents

Publication Publication Date Title
ES2174757B1 (es) Empleo de derivados de firazolinas en la elaboracion de un medicamentopara la prevencion y/o el tratamiento de enfermedades proliferativas celulares.
CO5031241A1 (es) Derivados de pirazolinas, su preparacion y su aplicacion como medicamentos
ATE327977T1 (de) Tetrahydrochinolin-derivate als crth2 antagonisten
LV10575A (lv) Izoksazoi-4-karbonskabes amids un hidroksialkiliden-cianetikskabes amids sos savienojumus saturosi astniecibas lidzekli un to pielietojums
AR038868A1 (es) Derivados de 1-(2-aminoacetil)2-pirrolidincarbonitrilo, su uso para la preparacion de una formulacion farmaceutica, las formulaciones farmaceuticas que los contienen, un procedimiento para la preparacion de estos derivados, y los intermediarios y su uso en dicho procedimiento de preparacion
PE20040599A1 (es) Amidas sustituidas como moduladores del receptor cannabinoide-1 (cb1)
HUP0402376A2 (hu) Imidazol-4-karboxamid-származékok, előállításuk és az ezeket tartalmazó, elhízás kezelésére alkalmas gyógyszerkészítmények
PE20020504A1 (es) N-acilsulfonamidas promotoras de apoptosis
DK1786790T3 (da) Oxazolderivater som histamin H3 receptorstoffer, fremstilling og terapeutiske anvendelser
TW200510353A (en) Alpha substituted carboxylic acids as PPAR modulators
NZ527249A (en) Purine derivatives as purinergic receptor antagonists
CY1107703T1 (el) Υποκατεστημενες δικετοπιπεραζινες και χρηση αυτων ως ανταγωνιστες οξυτοκινης
DE602004006869D1 (de) 5ht2c rezeptor agonisten zur behandlung von diabetes und fettleibigkeit
SE7605819L (sv) Nya propargyl-2-fenylaminoimidazolin-(2), dess syraadditionssalter, lekemedel innehallande dessa och forfarande for framstellning derav
DE69711868D1 (de) Adenosin-derivate
ATE111460T1 (de) 2-(aminoalkyl)-5-(arylalkyl)1,3-dioxanderivate, ihre herstellung und ihre anwendung in der therapeutik.
MXPA04003278A (es) Derivados de 5-metoxi-8-aril-?1,2,4?triazolo?1,5-a?piridina como antagonistas del receptor de adenosina.
SE0101978D0 (sv) New compounds
HUP0201863A2 (hu) Új morfolinszármazékok, eljárás előállításukra és azokat tartalmazó gyógyszerkészítmények
HUP0303612A2 (hu) Biciklusos guanidinszármazékok és ezek terápiás alkalmazása
AR039713A1 (es) Derivados de acido benzoico orto sustituidos para el tratamiento de resistencia a la insulina
ATE356805T1 (de) Oxophenylcyclohexylpropanolaminderivate, deren herstellung und verwendung in therapeutika
KR910000143A (ko) 간질치료제로서의 5-페닐-2- 푸란 에스테르 및 아미드의 용도
ATE334675T1 (de) Arzneimittel enthaltend substituierte 2,5- diaminomethyl-1h-pyrrole
AR011799A1 (es) Benzamidas que tienen afinidad por el receptor d4 de dopamina, composicion farmaceutica, uso para la fabricacion de medicamentos y procedimiento deobtencion

Legal Events

Date Code Title Description
EC2A Search report published

Date of ref document: 20021101

Kind code of ref document: A1

Effective date: 20021101

FG2A Definitive protection

Ref document number: 2174757B1

Country of ref document: ES

FD2A Announcement of lapse in spain

Effective date: 20170216